Skip to main content

Table 4 Mean percent difference in BMD between affected and contralateral side in sarcoma patients

From: Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients

   

Mean (95% CI)

Mean (95% CI)

Mean (95% CI)

 

Location

n=

aBMD (g/cm2)

vBMD (g/cm3)

BMC (g)

FN

UpEx

10

-1.3 (-5.8 to 3.3)

-3.2 (-10.2 to 3.9)

3.3 (-5.6 to 12.1)

 

Femur/Tibia

22

-13.7 (-18.8 to -8.5)

-12.7 (-20.1 to -5.3)

-13.6 (-18.1 to -9.1)

 

Pelvis/Fibula

7

-7.1 (-14.6 to 0.4)

-6.2 (-13.8 to 1.5)

-7.8 (-15.5 to 0.0)

Calc

UpEx

8

-4.4 (-9.3 to 0.4)

 

-4.3 (-9.0 to 0.5)

 

Femur/Tibia

19

-22.5 (-30.1 to -15.0)

 

-22.6 (-30.1 to -15.1)

 

Pelvis/Fibula

6

-18.8 (-47.9 to 10.3)

 

-18.9 (-47.8 to 10.0)

  1. * Lower extremity sarcoma patients subgrouped into sarcomas within the vicinity of primary weight-bearing joints (femur/tibia) and pelvis/fibula.
  2. CI = confidence interval, aBMD = areal bone mineral density (g/cm 2 ), vBMD = volumetric bone mineral density (g/cm 3 ), BMC = bone mineral content (g), UpEx = Upper Extremity, FN =femoral neck, Calc = calcaneus